PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsPasireotide
Signifor lar kit, Signifor(pasireotide)
Signifor (pasireotide) is a protein pharmaceutical. Pasireotide was first approved as Signifor on 2012-04-24. It is used to treat cushing syndrome in the USA. It has been approved in Europe to treat acromegaly and pituitary acth hypersecretion. The pharmaceutical is active against somatostatin receptor type 3, somatostatin receptor type 1, somatostatin receptor type 2, and somatostatin receptor type 5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
endocrine system diseasesD004700
Trade Name
FDA
EMA
Signifor
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pasireotide pamoate
Tradename
Company
Number
Date
Products
SIGNIFOR LAR KITRecordatiN-203255 RX2014-12-15
5 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
signiforNew Drug Application2024-07-16
signifor larNew Drug Application2024-07-16
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cushing syndromeEFO_0003099D003480E24
Agency Specific
FDA
EMA
Expiration
Code
PASIREOTIDE PAMOATE, SIGNIFOR LAR KIT, RECORDATI RARE
2025-06-29ODE-268
Patent Expiration
Patent
Expires
Flag
FDA Information
Pasireotide Pamoate, Signifor Lar Kit, Recordati Rare
93519232028-05-23DP
74737612026-12-14DS, DP
77593082026-10-25DP
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
H01: Pituitary and hypothalamic hormones and analogues
H01C: Hypothalamic hormones
H01CB: Somatostatin and analogues
H01CB05: Pasireotide
HCPCS
Code
Description
J2502
Injection, pasireotide long acting, 1 mg
Clinical
Clinical Trials
84 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pituitary acth hypersecretionD047748EFO_1001110E24.0112
Acth-secreting pituitary adenomaD049913112
Neuroendocrine tumorsD018358EFO_1001901D3A.8112
Prostatic neoplasmsD011471C6111
MelanomaD00854511
Pituitary neoplasmsD01091111
Pituitary diseasesD010900E23.711
Dumping syndromeD004377EFO_1001307K91.111
AcromegalyD00017211
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8011
Carcinoid tumorD002276D3A.0011
HypoglycemiaD007003E16.211
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePasireotide
INNpasireotide
Description
Pasireotide is a six-membered homodetic cyclic peptide composed from L-phenylglycyl, D-tryptophyl, L-lysyl, O-benzyl-L-tyrosyl, L-phenylalanyl and modified L-hydroxyproline residues joined in sequence. A somatostatin analogue with pharmacologic properties mimicking those of the natural hormone somatostatin; used (as its diaspartate salt) for treatment of Cushing's disease. It has a role as an antineoplastic agent. It is a homodetic cyclic peptide and a peptide hormone. It is a conjugate base of a pasireotide(2+).
Classification
Protein
Drug classpeptides: inhibition of growth hormone release
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O
Identifiers
PDB
CAS-ID396091-73-9
RxCUI
ChEMBL IDCHEMBL3039583
ChEBI ID
PubChem CID9941444
DrugBankDB06663
UNII ID98H1T17066 (ChemIDplus, GSRS)
Target
Agency Approved
SSTR5
SSTR5
Organism
Homo sapiens
Gene name
SSTR5
Gene synonyms
NCBI Gene ID
Protein name
somatostatin receptor type 5
Protein synonyms
somatostatin receptor subtype 5
Uniprot ID
Mouse ortholog
Sstr5 (20609)
somatostatin receptor type 5 (Q3UZM7)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,389 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,438 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use